Novo Nordisk A/S (NYSE:NVO) is Navellier & Associates Inc.’s 7th Largest Position

Navellier & Associates Inc. decreased its stake in Novo Nordisk A/S (NYSE:NVO) by 5.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 118,465 shares of the company’s stock after selling 7,346 shares during the period. Novo Nordisk A/S makes up 1.9% of Navellier & Associates Inc.’s portfolio, making the stock its 7th biggest position. Navellier & Associates Inc.’s holdings in Novo Nordisk A/S were worth $14,106,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently modified their holdings of the company. 1620 Investment Advisors Inc. purchased a new stake in shares of Novo Nordisk A/S in the second quarter worth about $25,000. Strategic Investment Solutions Inc. IL purchased a new stake in shares of Novo Nordisk A/S in the second quarter worth about $25,000. Gilliland Jeter Wealth Management LLC boosted its position in shares of Novo Nordisk A/S by 200.0% in the second quarter. Gilliland Jeter Wealth Management LLC now owns 180 shares of the company’s stock worth $26,000 after buying an additional 120 shares during the period. Halpern Financial Inc. boosted its position in shares of Novo Nordisk A/S by 113.0% in the second quarter. Halpern Financial Inc. now owns 213 shares of the company’s stock worth $30,000 after buying an additional 113 shares during the period. Finally, Abound Wealth Management boosted its position in shares of Novo Nordisk A/S by 257.4% in the second quarter. Abound Wealth Management now owns 218 shares of the company’s stock worth $31,000 after buying an additional 157 shares during the period. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Down 2.0 %

NYSE:NVO opened at $103.17 on Thursday. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43. The business’s 50 day moving average is $116.80 and its two-hundred day moving average is $129.11. Novo Nordisk A/S has a 52 week low of $94.73 and a 52 week high of $148.15. The company has a market cap of $462.98 billion, a PE ratio of 34.08, a P/E/G ratio of 1.32 and a beta of 0.42.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the company. BMO Capital Markets decreased their target price on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a research report on Thursday, October 17th. Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. Finally, StockNews.com raised Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a report on Friday, November 1st. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $144.50.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.